A detailed history of Black Rock Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Black Rock Inc. holds 3,044,973 shares of CSTL stock, worth $96.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,044,973
Previous 2,595,687 17.31%
Holding current value
$96.8 Million
Previous $57.5 Million 15.3%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$18.84 - $24.94 $8.46 Million - $11.2 Million
449,286 Added 17.31%
3,044,973 $66.3 Million
Q1 2024

May 10, 2024

BUY
$18.06 - $25.3 $5.64 Million - $7.91 Million
312,488 Added 13.69%
2,595,687 $57.5 Million
Q4 2023

Feb 13, 2024

BUY
$12.19 - $22.43 $1.79 Million - $3.3 Million
147,019 Added 6.88%
2,283,199 $49.3 Million
Q3 2023

Nov 13, 2023

BUY
$13.28 - $20.3 $59,494 - $90,944
4,480 Added 0.21%
2,136,180 $36.1 Million
Q2 2023

Aug 11, 2023

BUY
$11.66 - $26.0 $141,587 - $315,718
12,143 Added 0.57%
2,131,700 $29.2 Million
Q1 2023

May 12, 2023

SELL
$19.47 - $28.49 $80,430 - $117,692
-4,131 Reduced 0.19%
2,119,557 $48.2 Million
Q4 2022

Feb 13, 2023

BUY
$18.08 - $30.0 $1.48 Million - $2.46 Million
81,864 Added 4.01%
2,123,688 $50 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $395,478 - $602,968
17,569 Added 0.87%
2,041,824 $53.3 Million
Q2 2022

Aug 12, 2022

BUY
$16.0 - $45.99 $3.87 Million - $11.1 Million
241,717 Added 13.56%
2,024,255 $44.4 Million
Q1 2022

May 12, 2022

SELL
$33.17 - $46.98 $625,221 - $885,526
-18,849 Reduced 1.05%
1,782,538 $80 Million
Q4 2021

Feb 10, 2022

BUY
$39.06 - $67.58 $1.77 Million - $3.07 Million
45,379 Added 2.58%
1,801,387 $77.2 Million
Q3 2021

Nov 09, 2021

BUY
$60.13 - $77.6 $3.85 Million - $4.97 Million
64,010 Added 3.78%
1,756,008 $117 Million
Q2 2021

Aug 11, 2021

BUY
$50.07 - $76.78 $84.7 Million - $130 Million
1,691,998 New
1,691,998 $124 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $836M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.